Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis

OBJECTIVE: To investigate whether blood–brain barrier (BBB) permeability, as measured by dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI), can provide early detection of suboptimal treatment response in relapsing–remitting multiple sclerosis (RRMS). METHODS: Thirty‐five RRMS patients s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Neurol
Autors principals: Cramer, Stig P., Simonsen, Helle J., Varatharaj, Aravinthan, Galea, Ian, Frederiksen, Jette L., Larsson, Henrik B. W.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6032831/
https://ncbi.nlm.nih.gov/pubmed/29604233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25219
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars